Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Int J Pharm ; 587: 119639, 2020 Sep 25.
Artigo em Inglês | MEDLINE | ID: mdl-32673772

RESUMO

This study aimed to synthesize silymarin nanoparticles (SILNPs) using chitosan nanoparticles as a delivery system and to evaluate their protective effects against CCl4 in rats. Eight groups of male Sprague-Dawley rats were treated for three weeks included the control group, CCl4-treated group (100 mg/kg b.w twice a week); SIL-treated group (50 mg/lg b.w); the groups treated daily with low dose (LD) or high dose (HD) of SILNPs (25, 50 mg/kg b.w) and the groups treated with CCl4 plus SIL, SILNPs (LD) or SILNPs (HD). Blood and tissue samples were collected for different assays. The synthesized SILNPs showed a smooth rounded shape with average particle size of 100 ± 2.8 nm. SILNPs contain the same compounds found in raw SIL and the in vitro release of SILNPs continues till 24 h. The in vivo study revealed that SIL and SILNPs at the low or high dose induced a significant improvement in the hematological parameters, liver and kidney function, lipid profile, serum cytokines, gene expression DNA fragmentation and histology of liver and kidney tissue resulted from CCl4. It could be concluded that SILNPs can be applied in oral delivery formulations with a potential application value for liver disease therapy.


Assuntos
Doença Hepática Induzida por Substâncias e Drogas , Nanopartículas , Silimarina , Animais , Antioxidantes/metabolismo , Tetracloreto de Carbono/toxicidade , Doença Hepática Induzida por Substâncias e Drogas/metabolismo , Fígado/metabolismo , Masculino , Estresse Oxidativo , Extratos Vegetais , Ratos , Ratos Sprague-Dawley , Silimarina/farmacologia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...